Asthma bronchiale – Aktuelle Diagnostik und Therapie

详细信息    查看全文

• 作者：Dr. T. Bahmer ; Prof. Dr. K. F. Rabe
• 关键词：SchlüsselwörterAtemwegsentzündung ; Phänotypen ; TH2 ; Zellen ; Lungenfunktionstests ; Kortikosteroide
• 刊名：Der Pneumologe
• 出版年：2016
• 出版时间：November 2016
• 年：2016
• 卷：13
• 期：6
• 页码：425-438
• 全文大小：687 KB
• 刊物主题：Pneumology/Respiratory System; Medicine/Public Health, general; Allergology; Internal Medicine; Infectious Diseases; Oncology;
• 出版者：Springer Berlin Heidelberg
• ISSN：1613-6055
• 卷排序：13

文摘

Bronchial asthma is a heterogeneous disease characterized by chronic airway inflammation. Different phenotypes can be distinguished based on the underlying type of inflammatory reaction (i.e. T_H2 vs. non-T_H2 cells), which is particularly important for patients with severe therapy refractive asthma, as new therapeutic strategies are directly targeted against T_H2-associated cytokines. Besides symptom control, successful asthma therapy also requires avoidance of exacerbations and fixed airflow limitation as well as the control of pharmacological side effects; therefore, early treatment with low-dose inhaled corticosteroid therapy (ICS) is required, if necessary in combination with a long-acting beta-2 agonist (LABA), preferably as fixed ICS/LABA combination. Before intensifying ICS therapy various factors, such as the inhalation technique have to be checked. Following increased dosage, controlled approaches to reduce ICS dosage again should not be forgotten in order to minimize drug side effects.